Kytopen, a biotechnology company at the forefront of advanced cell engineering solutions, has announced the appointment of Michael Chiu, Ph.D., as its Chief Executive Officer. He joins Kytopen to bolster its fundraising, product development, and marketing launch capabilities. With a proven track record in bringing new technologies to fruition, Dr. Chiu succeeds Paulo A. Garcia, Ph.D., one of the founders at Kytopen, who will now serve as an advisor.
Dr. Chiu recently joined Kytopen at the time of its exciting roll-out of the Flowfect® technology to renowned U.S. academic medical centers. Before this, he was the CEO of Erbi Biosystems, Inc., which was successfully acquired by multinational giant Merck KGaA in 2020. Earlier in his career, he held the role of CTO and other senior positions at Automation Engineering Inc, Trophos Energy, and Teradyne. His extensive educational profile includes a B.S. in mechanical engineering from the University of Minnesota, an M.S. and Ph.D. from MIT, and an M.B.A. from the prestigious Sloan Fellows program at MIT.
Kytopen’s remarkable suite of genome engineering tools has proven its exceptional performance, prompting the company to expand and deliver the revolutionary technology for wider use. Dr. Chiu’s vast experience in commercializing life science instrumentation makes him an ideal leader to spearhead Kytopen’s next stage of growth. The Board of Directors acknowledges Dr. Garcia for his pioneering work in transitioning the Kytopen technology from its MIT roots to a reliable platform. We share his vision for this disruptive technology, which will revolutionize cell therapy development and manufacturing to ultimately benefit patients around the world.
Dr. Garcia expressed his pride and optimism in the journey of Kytopen’s Flowfect® technology from its origin at MIT to significant biotech partners around the world. He went on to applaud the incoming leadership of Dr. Chiu, expressing his faith in her ability to successfully steer the company through a period of accelerated growth.
Dr. Chiu is thrilled to be working with Kytopen’s innovative team to open up access and extend the reach of their breakthrough, cost-effective, and labor-saving non-viral gene delivery platform for developing and manufacturing the next generation of life-saving cell therapies. With the increasing number of Flowfect Discover™ systems being deployed at leading academic medical centers and industry partners around the globe, Kytopen is poised to revolutionize how we discover and produce these essential treatments.
Revolutionizing the development, production, and monetization of gene-modified therapeutics, Kytopen unveiled their revolutionary Flowfect® platform in May 2023. Coupling microfluidics and automation, Flowfect will empower industry-leading CDMOs and medical centers to conquer the costly and time-intensive manufacturing challenges they typically face. With the launch of the automated high-throughput Flowfect Discover™ and the introduction of Flowfect Tx™ for large-scale delivery, Kytopen promises unprecedented results in genome engineering, dramatically reducing cost and accelerating the discovery of potentially lifesaving therapies.